2012-01-26 11:49:48 -
Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 - a new market research report on companiesandmarkets.com
The global benign prostatic hyperplasia (BPH) therapeutics market was estimated to be worth $3.2 billion in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 6.4% for the next eight years to reach $5.2 billion by 2018. This growth rate is primarily attributed to the recent and impending patent expiry of Uroxatral and Avodart/Avolve in the US and the EU. However, the strong pipeline is set to offset the depleting revenues with the expected launch of Cialis and NX-1207 in the near future. The increase in the elderly population is expected to be a major driver of the BPH therapeutics market.
Benign Prostatic Hyperplasia Therapeutics Market has Strong Competition Between Several Generics and a Few Branded
Products
We analyzed the current competitive landscape of the BPH therapeutics market and found the competition to be strong. The marketed products for the treatment of BPH include finasteride, dutasteride (Avodart/Avolve), tamsulosin, doxazosin, alfuzosin, terazosin and silodosin (Rapaflo/Uricef). Competition in the BPH therapeutics market is driven not only by product characteristics, such as their efficacy and safety profile, but also by market characteristics, such as the number of competitors, pricing and the introduction of generics.
The BPH therapeutics market has witnessed a number of patent expiries of major marketed products, such as finasteride (Proscar), doxazosin (Cardura XL), tamsulosin (Flomax), terazosin (Hytrin) and alfuzosin (Uroxatral). The patents for silodosin (Rapaflo) and dutasteride (Avodart) are set to expire in 2013 and 2015, respectively, in the US. These major products are likely to be substituted by lower-priced generics. The substitution of these products with cheaper generics will trigger a price war scenario and competition in the BPH therapeutics market will intensify in the future.
Duodart/Jalyn, a fixed-dose combination of dutasteride and tamsulosin, has received Marketing Authorization Application (MAA) approval in Europe and New Drug Application (NDA) approval in the US. The drug has an improved efficacy and safety profile over the currently marketed products. This implies that Duodart/Jalyn will provide strong competition for the currently marketed products. The competition in the BPH therapeutics market will further intensify with the launch of strong pipeline candidates that have improved therapeutic outcomes.
Strong Clinical Pipeline with Several First-in-Class Molecules
We analyzed the BPH therapeutic pipeline and found it to be strong. The pipeline for BPH therapeutics consists of approximately 21 molecules in different stages of development. More than 80% of the BPH therapeutics pipeline is captured by first-in-class molecules. Most of these molecules hold promise, with a novel mechanism of action and good efficacy and safety profiles. The BPH therapeutics pipeline does not have any me-too molecules. Eli Lilly´s Cialis is one of the most promising molecules that been filed with the US FDA (Food and Drug Administration) for marketing approval to treat BPH. Nymox´s NX-1207 is a novel injectable therapy and is expected to be launched in the US and the EU by 2014, which will drive the saturated BPH therapeutics market.
Benign Prostatic Hyperplasia Therapeutic Market has Moderate Unmet Need
We have found that the global BPH therapeutics market is a lucrative market with moderate unmet needs. The BPH therapeutics market has a number of products with moderate to high efficacy and moderate safety profiles. Although most marketed products have an acceptable efficacy and safety profile, there is an underlying opportunity to improve therapeutic outcomes.
Treatment options such as finasteride, dutasteride, tamsulosin, doxazosin, alfuzosin, terazosin and silodosin have moderate to high efficacy in the improvement of BPH symptoms, peak urine flow rate, prostate volume (PV) and decreasing the need for surgery. The safety profiles of these marketed products are moderate and can have adverse effects such as erectile dysfunction, retrograde ejaculation, impotency, decreased libido and breast disorders. In summary, the unmet need in the BPH therapeutics market is moderate and can be fulfilled by products that target under-served patient populations, offer improved safety profiles and are efficacious.
Report Overview
This report is an essential source of information and analysis on the global BPH market. The report identifies the key trends shaping and driving the global BPH market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global BPH sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.
Scope
The report provides information on the key drivers and challenges of the BPH market. Its scope includes
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) BPH market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as phosphodiesterase-5 (PDE5) inhibitors, apoptosis inducers, estrogen receptor agonist and vasopressin agonist.
- Analysis of the current and future competition in the seven key countries BPH market. Key market players covered are Eli Lilly and Company, and Nymox Pharmaceutical.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the BPH therapeutics market.
- Analysis of key recent licensing and partnership agreements in BPH market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global BPH market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global BPH market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What´s the next big thing in the global BPH market landscape? Identify, understand and capitalize.
Click for report details:
www.companiesandmarkets.com/Market-Report/benign-prostatic-hyper ..
Browse all Healthcare and Medical Market Research Reports
www.companiesandmarkets.com/healthcare-and-medical-market-resear ..
Browse all Healthcare and Medical Company Profile Reports
www.companiesandmarkets.com/healthcare-and-medical-company-profi ..
Browse all Latest Market Research Reports
www.companiesandmarkets.com/market-research-reports-p9.aspx?prk= ..
About Us
Companiesandmarkets.com is a leading online business information aggregator with over 500,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.coms online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest. Companiesandmarkets.com is focused on providing clients with exemplary customer service and a flexible approach to accessing business information. Our team have extensive expertise in the market research industry and are keen to provide clients advice on their research requirements and possible alternative sources of information; a model which provides clients a value for money solution to research.
